Black Diamond Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Black Diamond Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 26, 2026, to elect directors, ratify auditors, and vote on executive compensation.
NASDAQ
Black Diamond Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025.
NASDAQ
Black Diamond Therapeutics will hold its 2025 Annual Meeting of Stockholders online on June 12, 2025, to elect directors and ratify the appointment of its accounting firm.
NASDAQ
Black Diamond Therapeutics will hold its annual stockholders meeting virtually on June 6, 2024, to vote on key proposals including the election of directors and ratification of the company's accounting firm.
NASDAQ
Black Diamond Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, auditor ratification, and an amendment to limit officer liability.